From October 25 to 26, 2025, Xu Songshan, Chairman of the company, accepted an invitation from Wenzhou Medical University and attended the Inauguration Ceremony of the China-Thailand Biopharmaceutical Industry Alliance and the China-Thailand Friendly Institutional Cooperation and Exchange Event held in Wenzhou. This event aims to deepen industry-academia-research cooperation between China and Thailand in the biopharmaceutical field and jointly promote innovation in biopharmaceutical technologies and their industrial translation. On behalf of the company, Chairman Xu Songshan participated in the alliance signing ceremony and the launch ceremony of the China-Thailand Biopharmaceutical Industry Alliance, and delivered a speech during the exchange session, sharing NORTHLAND's experience in the research and development and clinical translation of gene therapy drugs.

As a high-tech enterprise specializing in the research and development of biopharmaceutical technologies, NORTHLAND has long been committed to the R&D and clinical translation of naked plasmid gene therapy drugs. Guided by the mission of “Creating Value, Serving Health,” the company has achieved breakthrough progress in its naked plasmid gene therapy drug development projects through continuous innovation. Currently, the company’s core product, “Cedoming Injection,” has entered the critical review stage for new drug application, and the company is making every effort to complete all preparatory work for commercialization.

At the signing ceremony, Chairman Xu Songshan stated that China and Thailand have strong complementary strengths in the biopharmaceutical sector and immense potential for cooperation. He expressed his hope that, through the China-Thailand Biopharmaceutical Industry Alliance platform, NORTHLAND could further deepen its collaboration with Thai universities, research institutions, and enterprises, jointly exploring the possibility of conducting clinical research and international multi-center clinical trials in Thailand. This initiative will not only accelerate NORTHLAND's global deployment of innovative drugs but also inject new momentum into the health initiatives of both countries' peoples.

Joining the China-Thailand Bio-pharmaceutical Industry Alliance not only highlights NORTHLAND's professional expertise in the field of gene therapy but also marks an important step for the company to expand its path toward internationalization. Taking this opportunity, the company will actively explore the Southeast Asian market and deepen cooperation in the pharmaceutical sector under the Belt and Road Initiative. Upholding the principles of innovation-driven development and open cooperation, NORTHLAND will join hands with global partners to contribute Chinese wisdom and strength to overcoming major diseases and safeguarding human health.